Stock 1795 LOTUS PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

End-of-day quote Taiwan S.E.
Other stock markets
 03:30:00 28/05/2024 am IST 		5-day change 1st Jan Change
280.5 TWD -0.71% Intraday chart for Lotus Pharmaceutical Co., Ltd. -2.09% +3.12%
11/05 Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
26/03 Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director
CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024
CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth
AQ
Transcript : Lotus Pharmaceutical Co., Ltd., Q3 2023 Earnings Call, Nov 14, 2023
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth
AQ
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.
CI
Lotus Pharmaceutical Co., Ltd. Announces Director Changes
CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda
CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia
BU
LOTUS PHARMACEUTICAL AND AMARIN CORPORATION PLC ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA
AQ
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
CI
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan
AQ
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment
MT
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson
CI
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1795 Stock
  4. News Lotus Pharmaceutical Co., Ltd.